Medullary Thyroid Cancer is an indication for drug development with over 40 pipeline drugs currently active. According to GlobalData, preregistered drugs for Medullary Thyroid Cancer have a 100% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Medullary Thyroid Cancer compared to historical benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Medullary Thyroid Cancer overview
Medullary thyroid cancer (MTC) is a rare and aggressive type of thyroid cancer that originates from the C cells, which produce calcitonin, a hormone that regulates calcium levels in the blood. MTC accounts for 5-10% of all thyroid cancers and can be sporadic or inherited. Sporadic MTC occurs randomly, while inherited MTC is associated with a genetic condition called multiple endocrine neoplasia type 2 (MEN2). Symptoms of MTC may include a lump in the neck, hoarseness, diarrhea, and flushing. The main treatment for MTC is surgery to remove the thyroid gland and sometimes the nearby lymph nodes. Other treatments, such as radiation or medication, may be used depending on the stage and spread of the cancer. Early detection and treatment of MTC can improve the prognosis and quality of life of patients.
For a complete picture of PTSR and LoA scores for drugs in Medullary Thyroid Cancer, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
